F/M Emerald Life Sciences Innovation ETF (LFSC) Fund Overview
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerF/M Emerald Life Sciences Innovation ETF (LFSC) trades at $43.40. The F/M Emerald Life Sciences Innovation ETF (LFSC) focuses on investing in innovative life science companies, primarily targeting U.S. equity securities. Sector: Financials.
Price as of · Last analyzed: Jun 14, 2026Analyst Coverage for LFSC: LFSC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
F/M Emerald Life Sciences Innovation ETF (LFSC) Financial Services Profile
The F/M Emerald Life Sciences Innovation ETF (LFSC) is an actively managed fund that strategically invests in pioneering life science enterprises, leveraging a rigorous research framework to identify high-growth potential companies in biotechnology, pharmaceuticals, and medical technologies.
What Is the Investment Thesis for LFSC?
The F/M Emerald Life Sciences Innovation ETF (LFSC) is positioned to capitalize on the growing demand for innovative healthcare solutions, with the global life sciences market projected to reach approximately $2.5 trillion by 2028. The fund's active management strategy allows it to adapt quickly to market changes and identify high-potential investments in small and mid-cap companies. Key value drivers include the fund's rigorous research framework, which enhances stock selection and risk management, as well as its focus on sectors experiencing rapid growth, such as biotechnology and medical devices. The absence of a dividend yield may appeal to growth-focused investors seeking capital appreciation. However, investors should be aware of the liquidity risks associated with the fund's relatively small market capitalization of $0.11 billion, which may affect larger institutional investors. Overall, LFSC's commitment to identifying disruptive technologies and innovative healthcare solutions positions it well for long-term value creation.
Based on FMP financials and quantitative analysis
LFSC Key Highlights
Market capitalization of $0.11 billion, indicating a focus on small to mid-cap investments.
- Actively managed fund with a rigorous 10-step research framework for stock selection.
- Investment primarily in U.S. equity securities, with up to 20% allocated to foreign companies on U.S. exchanges.
- Focus on sectors such as biotechnology, pharmaceuticals, and medical devices, which are experiencing rapid growth.
- No dividend yield, appealing to growth-oriented investors seeking capital appreciation.
Who Are LFSC's Competitors?
LFSC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| IBB iShares Biotechnology ETF | $205.29 | -0.33% | $10.1B | — |
| XBI State Street SPDR S&P Biotech ETF | $154.43 | -0.05% | $8.07B | — |
| VHT Vanguard Health Care ETF | $311.90 | +0.06% | $20.9B | — |
| PBE Invesco Biotechnology & Genome ETF | $95.07 | -0.03% | $290M | — |
| FSPGX Fidelity Large Cap Growth Index Fund | $49.87 | +1.09% | $49.5B | — |
| BLK BlackRock, Inc. | $1059.63 | -0.44% | $164B | 51 5-pillar |
| BX Blackstone Inc. | $111.74 | -0.45% | $135B | 68 5-pillar |
| APOS Apollo Global Management, Inc. | $25.59 | -0.23% | $74.8B | 56 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are LFSC's Key Strengths?
Active management allows for quick adaptation to market changes.
- Rigorous research framework enhances investment decision-making.
- Focus on high-growth sectors within life sciences offers substantial upside potential.
- Experienced management team with deep industry knowledge.
What Are LFSC's Weaknesses?
Relatively small market capitalization may pose liquidity risks.
- Lack of dividend yield may deter income-focused investors.
- Dependence on active management may lead to higher expense ratios.
- Limited brand recognition compared to larger, established funds.
What Are the Key Risks for LFSC?
Liquidity risks due to the fund's small market capitalization may affect larger investors.
- Market volatility could impact the fund's performance and investor sentiment.
- Regulatory changes in the life sciences sector may introduce new risks for the fund's investments.
What Threats Does LFSC Face?
- Intense competition from larger, established asset management firms.
- Market volatility may impact fund performance and investor sentiment.
- Regulatory changes affecting the life sciences sector could pose risks.
- Economic downturns may reduce investment in high-risk sectors.
What Are LFSC's Competitive Advantages?
- Rigorous 10-step research framework enhances stock selection and risk management.
- Active management allows for dynamic portfolio adjustments in response to market trends.
- Focus on small and mid-cap companies provides access to overlooked growth opportunities.
- Expertise in life sciences enables informed investment decisions based on industry insights.
- Flexibility to allocate capital to foreign companies increases investment diversification.
What Does LFSC Do?
The F/M Emerald Life Sciences Innovation ETF (LFSC) was established with a mission to strategically invest in pioneering life science enterprises that are well-positioned for substantial long-term growth. The fund operates under the premise that the life sciences sector is ripe with opportunities for innovation and disruption, particularly in areas such as biotechnology, pharmaceuticals, medical diagnostics and devices, healthcare services, and synthetic biology. LFSC is actively managed by a specialized team with extensive experience in conducting in-depth research into complex life sciences firms. This expertise allows the fund to identify companies that demonstrate strong growth potential based on specific criteria, including their leadership in technological advancement and innovative applications of artificial intelligence. The fund employs a rigorous 10-step research framework that includes reviews of publicly accessible information, peer reviews, financial modeling, in-house research, and direct engagement with company management and industry experts. While LFSC primarily focuses on U.S. equity securities, it retains the flexibility to allocate up to 20% of its capital to foreign companies listed on U.S. exchanges. This strategic approach enables LFSC to navigate the dynamic landscape of life sciences effectively, ensuring that it remains at the forefront of investment opportunities in this rapidly evolving sector.
What Products and Services Does LFSC Offer?
- Invest in pioneering life science companies with strong growth potential.
- Focus on U.S. equity securities while allowing up to 20% allocation to foreign firms listed on U.S. exchanges.
- Utilize a rigorous 10-step research framework for stock selection.
- Target sectors including biotechnology, pharmaceuticals, medical devices, and healthcare technologies.
- Engage directly with company management and industry experts for informed investment decisions.
- Adapt portfolio dynamically to capitalize on emerging trends in the life sciences sector.
How Does LFSC Make Money?
- Generate returns through capital appreciation by investing in high-growth life science companies.
- Utilize active management to adapt to market changes and identify investment opportunities.
- Employ a comprehensive research framework to enhance stock selection and risk management.
- Maintain flexibility in investment strategy to allocate capital across various life sciences sectors.
- Leverage industry expertise to conduct in-depth analysis of potential investments.
What Industry Does LFSC Operate In?
The asset management industry is increasingly focused on specialized investment strategies, particularly in sectors like life sciences that are poised for significant growth. The global life sciences market is projected to expand at a compound annual growth rate (CAGR) of around 7.5%, driven by advancements in biotechnology, pharmaceuticals, and healthcare technologies. Within this landscape, the F/M Emerald Life Sciences Innovation ETF (LFSC) seeks to differentiate itself by targeting small and mid-cap companies that are often overlooked by larger funds. This focus allows LFSC to capitalize on emerging trends and innovations that could lead to substantial returns as these companies grow and mature in the market.
Who Are LFSC's Key Customers?
- Institutional investors seeking exposure to innovative life sciences.
- Retail investors focused on growth-oriented investment strategies.
- Financial advisors looking for specialized funds to recommend to clients.
- Pension funds and endowments interested in diversifying portfolios with high-growth assets.
- Wealth management firms aiming to provide clients with access to cutting-edge life science investments.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
- ● This is an etf, not an operating company
LFSC Financials
Bull Case vs Bear Case
Bull Case
- Active management allows for quick adaptation to market changes.
- Rigorous research framework enhances investment decision-making.
- Focus on high-growth sectors within life sciences offers substantial upside potential.
- Experienced management team with deep industry knowledge.
Bear Case
- Relatively small market capitalization may pose liquidity risks.
- Lack of dividend yield may deter income-focused investors.
- Dependence on active management may lead to higher expense ratios.
- Limited brand recognition compared to larger, established funds.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · June 2026
LFSC Latest News
No recent news available for LFSC.
LFSC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for LFSC.
Price Targets
Wall Street price target analysis for LFSC.
LFSC MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for LFSC; grades run from A+ (80-100) to F (below 30).
Common Questions About LFSC (Financials)
What does F/M Emerald Life Sciences Innovation ETF do?
The F/M Emerald Life Sciences Innovation ETF (LFSC) strategically invests in pioneering life science companies, primarily focusing on U.S. equity securities with strong growth potential.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.